SYRS - サイロス・ファ―マシュ―ティカルズ (Syros Pharmaceuticals Inc.)

SYRSのニュース

   The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs  2020/08/19 11:32:33 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI ) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI ) DarioHealth Corp (NASDAQ: DRIO ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Otonomy Inc (NASDAQ: OTIC ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Pacira Biosciences Inc (NASDAQ: PCRX ) PDL BioPharma Inc (NASDAQ: PDLI ) Principia Biopharma Inc (NASDAQ: PRNB ) Qiagen NV (NYSE: QGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Silk Road Medical Inc (NASDAQ: SILK ) Syros Pharmaceuticals Inc (NASDAQ: SYRS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 18) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Interpace Biosciences Inc (NASDAQ: IDXG )(announced receipt of letters from recently departed employees regarding billing and compliance issues) Iterum Therapeutics PLC (NASDAQ: ITRM ) NanoVibronix Inc (NASDAQ: NAOV ) Poseida Therapeutics, Inc. (NASDAQ: PSTX )( announced clinical hold on its Phase 1 prostate cancer study) Predictive Oncology Inc (NASDAQ: POAI ) Recro Pharma Inc (NASDAQ: REPH ) Unity Biotechnology Inc (NASDAQ: UBX ) Stocks In Focus Venrock Reports Purchase of 451K Unum Shares Unum Therapeutics Inc (NASDAQ: UMRX ) shares advanced after Venrock Healthcare Partners III L.P. said in a filing it has purchased 451,000 shares of Unum's common stock in a series of transactions effected between Aug. 14 and Aug. 18, bringing the total number of shares owned by the fund to 4.355 million The stock climbed 16.24% to $3.15 in after-hours trading.
   Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2020/08/06 11:31:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events. “Despite the unforeseen challenges of recent months, our team at Syros has shown remarkable resiliency, continuing to execute with excellence as we advance our product candidates toward key data readouts and p
   Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/05 13:09:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as follows: 2020 Wedbush PacGrow Healthcare Virtual Conference: Date: Wednesday, August 12 Time: 8:00 a.m. ET A live webcast of the presentation will be available on the Invest
   Syros to Present Virtually at JMP Securities Hematology and Oncology Forum  2020/06/11 12:31:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows: JMP Securities Hematology and Oncology Forum Date: Thursday, June 18 Presentation Time: 4:00 p.m. ET A live webcast of the presentation will be available on the Investors &am
   Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program  2020/05/13 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31.
   Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/05 13:09:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as follows: 2020 Wedbush PacGrow Healthcare Virtual Conference: Date: Wednesday, August 12 Time: 8:00 a.m. ET A live webcast of the presentation will be available on the Invest
   Syros to Present Virtually at JMP Securities Hematology and Oncology Forum  2020/06/11 12:31:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows: JMP Securities Hematology and Oncology Forum Date: Thursday, June 18 Presentation Time: 4:00 p.m. ET A live webcast of the presentation will be available on the Investors &am
   Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program  2020/05/13 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31.
   Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones  2020/05/07 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2020 and provided an update on recent accomplishments and upcoming events. “While COVID-19 has created tremendous uncertainty across the globe, it has also reminded us of the critical importance of medical innovation,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Ov
   Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020  2020/04/30 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 1585949. A webcast of t
   Syros Pharmaceuticals EPS beats by $0.01, misses on revenue  2020/03/05 12:33:34 Seeking Alpha
Syros Pharmaceuticals (NASDAQ:SYRS): Q4 GAAP EPS of -$0.46 beats by $0.01. Revenue of $0.51M (-42.7% Y/Y) misses by $0.18M. Press Release
   Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2020/03/05 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended December 31, 2019, and provided an update on recent accomplishments and upcoming events. “We are entering 2020 in a position of strength,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Following the recent initiation of our Phase 1 trial of SY-5609, we are advancing two oral i
   Syros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release  2020/02/27 17:30:49 Zacks Investment Research
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020  2020/02/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 276426
   Syros to Present at Upcoming Investor Conferences in March  2020/02/24 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences: Cowen and Company 40th Annual Health Care Conference in Boston, MA on Monday, March 2, 2020 at 4:50 p.m. ET. Oppenheimer 30th Annual Healthcare Conference in New York, NY on Wednesday March 18, 2020 at 10:55 a.m. ET. Live webcasts of the presentations will be availabl

calendar